Roche More: Roche to present new data on personalised medicines and cancer immunotherapies at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting Source: MDlinx
read moreGermany’s Boehringer Ingelheim several years ago decided it wanted to expand its biologics contract manufacturing business and bet that China was the place to target with its huge population and growing appetite for the latest meds. The company has now
read moreIt’s been just a couple of weeks since we wrote up AstraZeneca’s Imfinzi approval in bladder cancer. But so much has happened in the immuno-oncology field over that short stretch that, frankly, we at FiercePharma aren’t sure we even recognize
read moreWhen Louisiana Attorney General Jeff Landry inherited an antitrust lawsuit levied against Pfizer by his predecessor in 2015, he spotted an opportunity to combat the state’s mounting opioid epidemic. The result is a settlement for $1 million worth of Pfizer’s
read moreAfter a patient taking Biogen’s Tecfidera died in 2014, the hot MS drug was slapped with a new FDA warning, lost ground in the marketplace—and soon, Biogen faced a securities lawsuit claiming it hid the negative fallout. Now, with a
read moreWith complex biologics making up a growing part of pipelines, drugmakers have been selling or closing small-molecule plants left and right. Sanofi is taking that process a couple of steps further. It will demolish a plant it spent about $118
read more© 1994 - 2026 B.M. Pharmaceuticals